Many patients with GIST who failed the commercially available TKI still have a good performance status and excellent organ function, and the high unmet medical need for novel therapies in these patients is illustrated by the common use of off-label therapies with other KIT or PDGFR inhibitors. Here, KIT is linked to gastrointestinal stromal tumor.